Executive leadership from Zoetis Inc. (NYSE: ZTS)—led by Chief Executive Officer Kristin Peck and Chief Financial Officer Jay Saccaro—outlined the company’s strategic outlook at the Morgan Stanley 24th Annual Global Healthcare Conference. Addressing institutional investors, executives confronted near-term headwinds in the competitive companion animal parasiticide sector while reiterating confidence in their long-term growth trajectory.
Navigating Parasiticide Pressures
The companion animal health sector has seen intensifying price competition and aggressive brand expansion in retail and veterinary distribution channels. While broad-spectrum oral parasiticides have traditionally served as major revenue anchors, Zoetis acknowledged soft short-term growth volume in select geographic markets due to promotional discounting by competitors.
Strategic Pivot: Next-Gen Biologics & Feline Therapeutics
To insulate revenues from generic or biosimilar erosion in standard small-molecule pharmaceuticals, Zoetis is focusing research and development (R&D) capital on high-barrier biopharmaceuticals:
-
Long-Acting Monoclonal Antibodies (mAbs): Building on its anti-nerve growth factor (anti-NGF) franchise, Zoetis highlighted recent commercial rollouts like Portela® (relfovetmab), a single-injection therapy delivering up to three months of osteoarthritis pain relief in cats.
-
Feline Dermatology Innovation: The company is advancing next-generation dermatological platforms targeting chronic feline pruritus and inflammatory skin conditions, extending the commercial success established by its canine therapies (Apoquel® and Cytopoint®).
